Pfizer offers up talents, tools and manufacturing capabilities in call for wide COVID-19 collabs

Many organizations and companies in the biopharma world have formed alliances to develop drugs and vaccines against the novel coronavirus amid a global pandemic. Now Pfizer, on top of its own bilateral team-up, is offering up its resources for wider use.

The New York pharma is openly sharing its drug development talents, tools and expertise, as well as its manufacturing capabilities, with any companies working on promising anti-COVID-19 candidates—and it’s calling on the entire biopharma industry to do the same.

To hear Pfizer chief Albert Bourla tell it, the COVID-19 pandemic isn’t a task any one player can tackle on its own.